| 1 |
NCT02169830 |
Recruiting |
Trial of Nortriptyline and Topiramate in the Initial Treatment of Vestibular Migraine |
|
- Drug: nortriptyline
- Drug: Topiramate
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- evaluate the comparative effectiveness of migraine diet, nortriptyline and topiramate
|
100 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT02169830 |
24482_ Vest_Migraine |
|
June 2014 |
July 2018 |
September 2018 |
June 23, 2014 |
October 25, 2017 |
|
- Saint Louis University
Saint Louis, Missouri, United States
|
| 2 |
NCT02562196 |
Recruiting |
tDCS for the Treatment of Migraine |
|
|
Interventional |
Phase 2 |
- Universidade Federal de Pernambuco
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Change in headache diary variables
- Changes on Visual Evoked Potentials measures
- Changes on HIT-6
- (and 5 more...)
|
14 |
All |
18 Years to 55 Years (Adult) |
NCT02562196 |
Effect_tDCS_Migraine |
|
March 2016 |
August 2016 |
April 2018 |
September 29, 2015 |
May 11, 2016 |
|
- Applied Neuroscience Laboratory
Recife, Pernambuco, Brazil
|
| 3 |
NCT03015753 |
Recruiting |
The Efficacy of Tai Chi Training for the Prophylaxis of Migraine in Chinese Women |
|
- Behavioral: Tai Chi training
- Other: Waiting list control group
|
Interventional |
Not Applicable |
- The Hong Kong Polytechnic University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- The difference in frequency of migraine attacks (the number of attacks per month)
- The proportion of responders
- Duration of headache attack
- (and 17 more...)
|
60 |
Female |
18 Years to 65 Years (Adult) |
NCT03015753 |
G-UA8P |
|
February 2016 |
April 2017 |
July 2017 |
January 10, 2017 |
January 11, 2017 |
|
- The Hong Kong Polytechnic University
Hung Hom, Hong Kong
|
| 4 |
NCT02562222 |
Recruiting |
Optimized tDCS for the Treatment of Migraine |
|
- Procedure: anodal tDCS on M1
- Procedure: cathodal tDCS on M1
- Procedure: anodal tDCS on V1
- (and 4 more...)
|
Interventional |
Phase 2 |
- Universidade Federal de Pernambuco
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Changes on VAS
- Changes on Visual Evoked Potentials measures
- Changes on motor evoked potentials
- (and 3 more...)
|
14 |
All |
18 Years to 55 Years (Adult) |
NCT02562222 |
Optimizing_tDCS_Migraine |
|
May 2016 |
August 2016 |
April 2018 |
September 29, 2015 |
May 11, 2016 |
|
- Applied Neuroscience Laboratory
Recife, Pernambuco, Brazil
|
| 5 |
NCT03484871 |
Recruiting
New |
Resting-state Functional Connectivity Changes During Migraine Treatment |
|
|
Observational |
|
- Samsung Medical Center
- SK Chemicals Co.,Ltd.
|
Other / Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- functional MRI imaging changes
- structural MRI imaging changes
- Functional and structural correlates of treatment response
- (and 2 more...)
|
30 |
Female |
18 Years to 50 Years (Adult) |
NCT03484871 |
2016-04-028 |
|
May 2016 |
November 2018 |
November 2018 |
April 2, 2018 |
April 2, 2018 |
|
- Samsung Medical Center
Seoul, Korea, Republic of
|
| 6 |
NCT03190044 |
Recruiting |
Magnesium, Partenium, Andrographis, Co-enzyme Q10 and Riboflavin (PACR) in Migraine Prophylaxis |
|
- Dietary Supplement: PACR
- Dietary Supplement: Placebo
|
Interventional |
Not Applicable |
- University of Roma La Sapienza
- Gianluca Coppola
- Francesco Pierelli
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Care Provider)
- Primary Purpose: Prevention
|
- Migraine improvement in terms of responder rate
- Migraine improvement in terms of frequencies
|
82 |
All |
18 Years to 65 Years (Adult) |
NCT03190044 |
ParMig Study |
ParMig |
June 6, 2017 |
November 30, 2017 |
December 31, 2017 |
June 16, 2017 |
June 16, 2017 |
|
- Policlinico Umberto I
Rome, Italy
|
| 7 |
NCT02817139 |
Recruiting |
Transcranial Direct Current Simulation in Chronic Migraine |
|
|
Interventional |
Phase 1
Phase 2 |
- Federal University of Paraíba
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in quality of life associate to migraine assessed on the Headache Impact Test-6 (HIT-6)
- Change in pain assessed on the Visual Analogue Scale (VAS)
- Change in quality of life assessed on the Medical Outcomes Study 36 - Item Short - Form Health Survey(SF-36)
- Side Effects Questionnaire
|
15 |
All |
18 Years to 65 Years (Adult) |
NCT02817139 |
migraine |
|
June 2016 |
June 2016 |
September 2016 |
June 29, 2016 |
June 29, 2016 |
|
- Suellen Andrade
João Pessoa, PB, Brazil
|
| 8 |
NCT02791997 |
Recruiting |
Audition After a Lesion and in Migraine. (AuditionPostLesion) |
- Migraine Disorders, Brain
|
- Other: Neuropsychological tests
- Other: Neurophysiological tests
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Percentages of correct responses in Neuropsychological tests
- reaction times in Neuropsychological tests
- Event-Related Potentials (EEG) in Neurophysiological tests
- Event-Related Fields (MEG) in Neurophysiological tests
|
335 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT02791997 |
69HCL14_0202 |
|
February 6, 2015 |
February 2019 |
February 2019 |
June 7, 2016 |
February 7, 2018 |
|
- Unité 201, Hôpital Neurologique
Bron, France - Service Explorations Fonctionnelles Neurologiques, Hôpital de la Croix-Rousse
Lyon, France
|
| 9 |
NCT03266588 |
Recruiting |
Open Label Safety Study in Acute Treatment of Migraine |
|
|
Interventional |
Phase 2
Phase 3 |
- Biohaven Pharmaceutical Holding Company Ltd.
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To assess the safety and tolerability of rimegepant (BHV-3000) by measuring the frequency and severity of adverse events and discontinuations due to adverse events
- ALT or AST > 3x ULN with total bilirubin >2x ULN
- hepatic related adverse events and hepatic related adverse events that lead to discontinuation
|
2000 |
All |
18 Years and older (Adult, Senior) |
NCT03266588 |
BHV3000-201 |
|
August 30, 2017 |
March 2019 |
April 2019 |
August 30, 2017 |
November 29, 2017 |
|
- Central Research Associates, Inc
Birmingham, Alabama, United States - Coastal Clinical Research, Inc.
Mobile, Alabama, United States - Thunderbird Internal Medicine / Radiant Research, Inc
Glendale, Arizona, United States - (and 95 more...)
|
| 10 |
NCT02748577 |
Recruiting |
Pain Processing in Adults With Migraines |
|
- Other: Questionnaires
- Other: Quantitative Sensory Testing (QST) Pain Measurements
|
Interventional |
Not Applicable |
- Wake Forest University Health Sciences
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Heat Pain Intensity coefficient and intercept from stimulus response curve
- Heat Pain Unpleasantness coefficient and intercept from stimulus response curve
- Pain Catastophizing score
- (and 13 more...)
|
98 |
All |
18 Years and older (Adult, Senior) |
NCT02748577 |
IRB00027845 |
|
January 2016 |
July 2020 |
July 2020 |
April 22, 2016 |
October 24, 2017 |
|
- Wake Forest University Health Sciences
Winston-Salem, North Carolina, United States
|
| 11 |
NCT03333109 |
Recruiting |
Study of Efficacy and Safety of AMG 334 in Adult Episodic Migraine Patients |
|
- Biological: Erenumab
- Other: Placebo
|
Interventional |
Phase 3 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Change from baseline in monthly migraine days at the last month (Month 3) of the double-blind treatment period (DBTP)
- Achievement of at least a 50% reduction from baseline in monthly migraine days at Month 3
- Change from Baseline in acute migraine-specific medication treatment days at Month 3
- Change from Baseline in headache impact scores as measured by the HIT-6 at Month 3
|
880 |
All |
18 Years to 65 Years (Adult) |
NCT03333109 |
CAMG334A2302 |
EMPOwER |
February 8, 2018 |
February 7, 2020 |
February 7, 2020 |
November 6, 2017 |
February 15, 2018 |
|
- Novartis Investigative Site
Beirut, Lebanon
|
| 12 |
NCT03108469 |
Recruiting |
Efficacy and Safety of IONIS-PKKRx for Preventive Treatment of Chronic Migraine |
|
- Drug: IONIS-PKKRx (ISIS 546254)
- Other: Placebo
|
Interventional |
Phase 2 |
- Smith, Timothy R., M.D.
- Clinvest Research, LLC
- Ionis Pharmaceuticals, Inc.
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Comparison of Adverse Events
- Change in Migraine Days
- Change in Headache Severity
- (and 6 more...)
|
30 |
All |
18 Years to 65 Years (Adult) |
NCT03108469 |
15-001IS |
|
August 1, 2017 |
December 31, 2018 |
December 31, 2018 |
April 11, 2017 |
April 17, 2018 |
|
- StudyMetrix
Saint Peters, Missouri, United States - Clinvest Research, LLC
Springfield, Missouri, United States
|
| 13 |
NCT03282227 |
Recruiting |
A Study to Evaluate the Long-Term Safety of M207 in the Acute Treatment of Migraine |
|
- Drug: M207 Microneedle System
|
Interventional |
Phase 3 |
- Zosano Pharma Corporation
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Long-term safety as measured by incidence of adverse events
- Proportion of subjects with pain freedom
- Proportion of subjects with most bothersome symptom freedom
- (and 4 more...)
|
250 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT03282227 |
CP-2017-001 |
ADAM |
November 7, 2017 |
March 2019 |
March 2019 |
September 13, 2017 |
March 2, 2018 |
|
- Achieve Clinical Research
Birmingham, Alabama, United States - Elite Clinical Studies
Phoenix, Arizona, United States - Downtown L.A. Research Center
Los Angeles, California, United States - (and 26 more...)
|
| 14 |
NCT02964741 |
Recruiting |
Investigation and Modulation of the Mu-Opioid Mechanisms in Migraine (in Vivo) |
|
- Device: Active Comparator
- Device: Sham Comparator
|
Interventional |
Not Applicable |
- University of Michigan
- National Institute of Neurological Disorders and Stroke (NINDS)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in pain intensity level measured by the Visual Analog Scale in migraineurs (active or sham)
- Change in mu-opioid receptor non-displaceable binding potential (BPND) in the brains of migraineurs during sustained thermal pain threshold stress challenge subsequent to treatment by HD-tDCS (active or sham).
- Change in mu-opioid receptor non-displaceable binding potential (BPND) in the brains of migraineurs at rest subsequent to treatment by HD-tDCS (active or sham).
|
90 |
All |
18 Years to 65 Years (Adult) |
NCT02964741 |
HUM00107286
R01NS094413 |
|
February 22, 2017 |
April 2020 |
June 2020 |
November 16, 2016 |
December 21, 2017 |
|
- University of Michigan School of Dentistry
Ann Arbor, Michigan, United States
|
| 15 |
NCT03414203 |
Recruiting |
Comparison Between Transcranial Stimulation Protocols With Continuous Current in the Chronic Migraine |
|
|
Interventional |
Not Applicable |
- Federal University of Paraíba
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Migraine Disability Assessment - MIDAS
- Headache Impact Test - HIT-6
- Wechsler Intelligence Scale Letters
- (and 10 more...)
|
45 |
Female |
20 Years to 45 Years (Adult) |
NCT03414203 |
NEUROMIG |
NEUROMIG |
August 14, 2017 |
February 5, 2018 |
April 16, 2018 |
January 29, 2018 |
January 29, 2018 |
|
- Federal University of Paraiba
João Pessoa, Paraiba, Brazil
|
| 16 |
NCT03152305 |
Recruiting |
Intracranial Pressure During Migraine |
|
- Other: Intracranial pressure variations
|
Observational |
|
- University Hospital, Clermont-Ferrand
|
Other |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- Intracranial pressure variations
- Relationships between ICP variations and clinical parameters
- Relationships between ICP variations and pain relief
|
60 |
Female |
18 Years to 50 Years (Adult) |
NCT03152305 |
CHU-331
2014-A00042-45 |
MigICP |
July 21, 2014 |
May 2017 |
July 2018 |
May 15, 2017 |
May 15, 2017 |
|
- CHU Clermont-Ferrand
Clermont-Ferrand, Auvergne, France
|
| 17 |
NCT03150797 |
Recruiting |
Melatonin for Adolescent Migraine Prevention Study |
|
- Drug: Melatonin
- Drug: Placebo oral capsule
|
Interventional |
Phase 2 |
- Amy Gelfand
- University of California, Los Angeles
- University of California, San Francisco
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Care Provider)
- Primary Purpose: Prevention
|
- Mean migraine/migrainous days in weeks 5-8 of randomized treatment phase in melatonin treated participants vs. placebo.
- Mean migraine/migrainous days in weeks 5-8 of randomized treatment phase in melatonin 6 mg vs. placebo.
- Mean migraine/migrainous days in weeks 5-8 of randomized treatment phase in melatonin 3 mg vs. placebo.
- (and 6 more...)
|
210 |
All |
10 Years to 17 Years (Child) |
NCT03150797 |
16-19623 |
MAP |
August 2, 2017 |
June 2021 |
June 2021 |
May 12, 2017 |
February 1, 2018 |
|
- UCLA Headache Research and Treatment Program
Los Angeles, California, United States - University of California, San Francisco, (UCSF)
San Francisco, California, United States
|
| 18 |
NCT03461757 |
Recruiting |
Trial in Adult Subjects With Acute Migraines |
|
- Drug: Rimegepant
- Drug: Placebo
|
Interventional |
Phase 3 |
- Biohaven Pharmaceutical Holding Company Ltd.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Pain freedom of rimegepant compared with placebo in the acute treatment of migraine will be measured using the number of evaluable subjects that report no pain at 2 hours post-dose.
- Freedom from the most bothersome symptom (MBS) of rimegepant compared with placebo will be measured using the number of evaluable subjects that report the absence of their MBS at 2 hours post-dose.
- Rimegepant compared to placebo from 2 to 24 hours, using the number of subjects that do not experience any headache pain through the time period of interest.
- (and 10 more...)
|
850 |
All |
18 Years and older (Adult, Senior) |
NCT03461757 |
BHV3000-303 |
|
February 27, 2018 |
August 3, 2018 |
August 15, 2018 |
March 12, 2018 |
March 29, 2018 |
|
- Baptist Health Center for Clinical Research
Little Rock, Arkansas, United States - Woodland International Research Group, LLC
Little Rock, Arkansas, United States - Pharmacology Research Institute
Encino, California, United States - (and 49 more...)
|
| 19 |
NCT02695498 |
Recruiting |
Mindfulness and Mechanisms of Pain Processing in Adults With Migraines |
|
- Other: Mindfulness Based Stress Reduction
- Other: Migraine/stress Education
|
Interventional |
Not Applicable |
- Wake Forest University Health Sciences
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in frequency of migraine days from baseline
- Change in migraine duration from baseline
- Change in migraine severity-pain intensity from baseline
- (and 22 more...)
|
98 |
All |
18 Years and older (Adult, Senior) |
NCT02695498 |
K23AT008406 |
|
March 2016 |
May 2019 |
June 2019 |
March 1, 2016 |
November 6, 2017 |
|
- Wake Forest University Health Sciences
Winston-Salem, North Carolina, United States
|
| 20 |
NCT03166046 |
Recruiting |
Migraine Prevention Using ActiPatch |
|
- Device: Pulsed Shortwave Therapy
- Device: Placebo Pulsed Shortwave therapy
|
Interventional |
Not Applicable |
- BioElectronics Corporation
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Migraine frequency
- Migraine duration
- Migraine intensity measured with Visual Analogue Pain Score
- Headache disability measured with Headache Impact Test
|
80 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT03166046 |
SAIRB-17-0021 |
PSWT |
June 1, 2017 |
April 21, 2018 |
April 30, 2018 |
May 24, 2017 |
March 22, 2018 |
|
- Eppley Group
Indianapolis, Indiana, United States
|
| 21 |
NCT03461874 |
Not yet recruiting |
ACT Therapy for HF Migraine |
|
- Behavioral: Education of patients
- Behavioral: ACT
- Drug: Pharmacological prophylaxis
|
Interventional |
Not Applicable |
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
- Brigham and Women's Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Reduction of headaches frequency
- Difference in the proportion of patients achieving the reduction of 50% or more of days with headache compared to baseline
- Medications intake
- (and 10 more...)
|
64 |
All |
18 Years to 65 Years (Adult) |
NCT03461874 |
ACT protocol |
ACTMigraine |
March 15, 2018 |
July 15, 2019 |
July 15, 2021 |
March 12, 2018 |
March 13, 2018 |
|
|
| 22 |
NCT03175900 |
Recruiting |
Effectiveness and Neural Mechanism of Naoan Dripping Pills for Migraine |
|
- Drug: Naoan dripping pills
- Drug: Placebo
|
Interventional |
Phase 4 |
- Dongzhimen Hospital, Beijing
- Liaoyuan Yulongdongya Pharmaceutical Co., Ltd.
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Responder rate
- Change in functional connectivity assessed by Resting-state fMRI
- Change in fractional anisotropy (FA) assessed by DTI
- (and 5 more...)
|
34 |
All |
18 Years to 65 Years (Adult) |
NCT03175900 |
PRO-2016-84-01 |
ENMNM |
June 17, 2017 |
March 2018 |
March 2018 |
June 5, 2017 |
January 12, 2018 |
|
- Dongzhimen Hospital
Beijing, Beijing, China
|
| 23 |
NCT02582996 |
Not yet recruiting |
Cefalium® Compared to Tylenol® in the Treatment of Migraine Attacks |
|
- Drug: Acetaminophen+Caffeine+Dihydroergotamine+Metoclopramide.
- Drug: Acetaminophen
|
Interventional |
Phase 3 |
- Ache Laboratorios Farmaceuticos S.A.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Pain relief of Cefalium® compared to Tylenol®
- Pain decrease after use of investigational product, without a rescue medication
- Pain decrease after use of the investigational product, without a rescue medication
- (and 4 more...)
|
336 |
All |
18 Years to 65 Years (Adult) |
NCT02582996 |
ACH-CFL-03(01/14) |
|
April 2019 |
April 2020 |
June 2020 |
October 21, 2015 |
April 12, 2018 |
|
- Centro de Pesquisa Clínica - CPEC / Associação Obras Sociais Irmã Dulce
Salvador, Bahia, Brazil - Centro de Pesquisa Clínica Hospital São Lucas da PUCRS
Porto Alegre, Rio Grande Do Sul, Brazil - Centro de Desenvolvimento em Estudos Clínicos Brasil - CDEC Brasil
São Paulo, Brazil - (and 3 more...)
|
| 24 |
NCT03275922 |
Recruiting |
Efficacy & Safety Of Zomig Nasal Spray For Acute Migraine Treatment In Subjects 6 To 11 Years, With OLE |
|
- Drug: Placebo ZNS
- Drug: ZNS
|
Interventional |
Phase 3 |
- IMPAX Laboratories, Inc.
- AstraZeneca
|
Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Pain-free status at 2 hours post treatment
- Proportion of subjects who achieve pain-free status at 24 hours post-dose
- Headache response at 24 hours post-dose
- Sustained headache response at 24 hours post-dose
|
426 |
All |
6 Years to 11 Years (Child) |
NCT03275922 |
IPX229-B16-01 |
|
December 4, 2017 |
April 2020 |
May 2020 |
September 8, 2017 |
March 12, 2018 |
|
- Advanced Research Center, Inc (134)
Anaheim, California, United States - Sierra Medical Research (124)
Fresno, California, United States - Newport Beach Clinical Research Assoicates, Inc. (108)
Newport Beach, California, United States - (and 31 more...)
|
| 25 |
NCT01230411 |
Recruiting |
A Double-blind, Placebo-controlled Pilot Study to Collect and Evaluate Data on the Use of Intravenous Ibuprofen in the Treatment of an Acute Migraine Attack |
|
- Other: saline placebo
- Drug: Ibuprofen
|
Interventional |
Phase 4 |
- Thomas Jefferson University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Comparison of proportion of subjects in control and active treatment groups who have pain relief at 2 hours after the completion of the double-blind treatment infusion.
|
120 |
All |
18 Years to 65 Years (Adult) |
NCT01230411 |
SDS/IVIb/01 |
|
June 2011 |
June 2017 |
December 2017 |
October 29, 2010 |
June 14, 2016 |
|
- Jefferson Headache Center
Philadelphia, Pennsylvania, United States
|
| 26 |
NCT02945839 |
Not yet recruiting |
Improving Health Outcomes of Migraine Patients Who Present to the Emergency Department |
|
- Drug: Preventative Medication (PM)
- Behavioral: Enhanced Usual Care
- Behavioral: PMR (progressive muscle relaxation therapy)
|
Interventional |
Phase 4 |
- New York University School of Medicine
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Migraine Disability Assessment Scale (MIDAS) at 3 Months and Baseline
- Perceived Stress Scale (PSS)
- Number of days/week treated with acute medications
- Number of drug administrations/week for acute medications
|
90 |
All |
18 Years to 64 Years (Adult) |
NCT02945839 |
16-00548 |
|
April 2018 |
December 2018 |
December 2018 |
October 26, 2016 |
January 23, 2018 |
|
- New York University School of Medicine
New York, New York, United States
|
| 27 |
NCT03081390 |
Recruiting |
Migraine and CVD Risk in Women |
|
- Other: Mixed meal tolerance testing
- Other: Skin conductance & cold pressor test
- Other: Flow-mediated dilation testing
|
Interventional |
Not Applicable |
- University of Pennsylvania
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- LPS area under the curve (AUC)
- Flow-mediated dilation (FMD)
- Sympathetic tone at rest and with painful stimulus
|
30 |
Female |
18 Years to 29 Years (Adult) |
NCT03081390 |
826251 |
|
April 1, 2017 |
September 2018 |
September 2018 |
March 16, 2017 |
April 10, 2018 |
|
- University of Pennsylvania
Philadelphia, Pennsylvania, United States - Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
|
| 28 |
NCT02686034 |
Recruiting |
RCT of Non-Invasive Vagus Nerve Stimulation (nVNS) With gammaCore®, for the Acute Treatment of Migraine Attacks |
|
- Device: gammaCore-S
- Device: gammaCore-S Sham
|
Interventional |
Not Applicable |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Treatment Response - No Pain
- Nausea/Vomiting
- Treatment Response - No Pain or Mild Pain
- Sustained Treatment Response
|
300 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT02686034 |
GM-16 |
|
January 2016 |
December 2016 |
April 2017 |
February 19, 2016 |
November 28, 2016 |
|
- University Aldo Moro, Ospedale Pediatrico
Bari, Italy - IRCCS Istituto delle Scienze Neurologiche di Bologna, Ospedale Bellaria
Bologna, Italy - University Hospital of Careggi
Florence, Italy - (and 7 more...)
|
| 29 |
NCT02443519 |
Recruiting |
Bronx MBCT-Migraine |
|
- Behavioral: MBCT for Migraine
|
Interventional |
Not Applicable |
- Albert Einstein College of Medicine, Inc.
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Migraine Disability Assessment
- Headache-Related Disability Index
- Headache Days (over course of 1 month)
- (and 9 more...)
|
80 |
All |
18 Years to 65 Years (Adult) |
NCT02443519 |
2015-4684 |
BMBCT-M |
May 2015 |
September 2018 |
July 2019 |
May 14, 2015 |
January 16, 2018 |
|
- Yeshiva University
Bronx, New York, United States
|
| 30 |
NCT02938182 |
Not yet recruiting |
Migraine Prophylaxis With Clopidogrel Trial |
|
|
Interventional |
Phase 4 |
- First Affiliated Hospital Xi'an Jiaotong University
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change from Baseline Attack Duration of Headache at three months, h
- Change from Baseline Headache Frequency per Month at three months, time
- Change from Baseline Visual Analogue Scale at three months, scores
- (and 2 more...)
|
50 |
All |
18 Years to 65 Years (Adult) |
NCT02938182 |
XJTU1AF-CRS-2016-019 |
|
October 2016 |
October 2017 |
October 2018 |
October 19, 2016 |
October 19, 2016 |
|
- First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, China
|
| 31 |
NCT03167060 |
Recruiting |
BrainCool-Migraine Intranasal Cooling Trial |
|
- Device: Active RhinoChill
- Device: Control Rhinochill
|
Interventional |
Not Applicable |
- Cumbria Partnership NHS Foundation Trust
- BrainCool AB
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- Participant is pain free at two hours following trial device treatment The patients' first treatment will be used for analysis of the superiority of the rate of patients pain free at two hours following treatment for those receiving the standard R
- Percentage of patients pain free immediately after treatment (10 minutes), at 1 hour, and 24 hours following treatment
- Headache response
- (and 3 more...)
|
90 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT03167060 |
CP1628 |
|
May 8, 2017 |
September 30, 2018 |
November 30, 2018 |
May 25, 2017 |
November 8, 2017 |
|
- Neurosciences department, Penrith Hospital, Cumbria Partnership NHS Foundation Trust
Penrith, Cumbria, United Kingdom - South tees Hospital
Middlesbrough, United Kingdom - The Newcastle upon Tyne Hospitals
Newcastle upon Tyne, United Kingdom - City Hospital, Sunderland, UK
Sunderland, United Kingdom
|
| 32 |
NCT03481400 |
Recruiting
New |
CGRP-induced Migraine Attacks in Patients Who Have Tried Anti-CGRP Monoclonal Antibody Treatment |
|
- Drug: Calcitonin Gene-Related Peptide
- Other: Placebo
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Other
|
- Incidence of migraine
- Area under the curve of headache intensity
- Heart rate
- Blood pressure
|
40 |
All |
18 Years to 65 Years (Adult) |
NCT03481400 |
H-16014580 |
|
July 2016 |
September 2019 |
September 2019 |
March 29, 2018 |
March 29, 2018 |
|
- Danish Headache Center, Rigshospitalet Glostrup
Copenhagen, Glostrup, Denmark
|
| 33 |
NCT03494673 |
Not yet recruiting
New |
Prediction of WMH in Migraine Using a BOLD-CVR Map |
|
- Diagnostic Test: BOLD MRI
|
Observational |
|
- Samsung Medical Center
- National Research Foundation of Korea
|
Other |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- CVR association with WMH development
- Spatial pattern of CVR
|
100 |
All |
18 Years to 50 Years (Adult) |
NCT03494673 |
2017-04-049 |
|
May 30, 2018 |
February 28, 2019 |
February 28, 2020 |
April 11, 2018 |
April 11, 2018 |
|
|
| 34 |
NCT03404336 |
Not yet recruiting |
Study on 30 Outpatients With Chronic Migraine Treated With Well-Being Therapy or With a Control Therapy |
|
- Behavioral: Well-Being Therapy
- Other: Control condition
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- disability due to migraine
- frequency of migraine attacks
- duration of migraine attacks
- (and 4 more...)
|
30 |
All |
18 Years to 65 Years (Adult) |
NCT03404336 |
WBT in MIG |
|
June 1, 2018 |
May 30, 2019 |
May 30, 2019 |
January 19, 2018 |
January 19, 2018 |
|
- Fiammetta COSCI
Florence, Italy
|
| 35 |
NCT03499119 |
Not yet recruiting
New |
AMG 334 20160172 Pediatric Migraine PK Study. |
|
- Drug: AMG 334 Dose 1
- Drug: AMG 334 Dose 2
- Drug: AMG 334 Dose 3
|
Interventional |
Phase 1 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Serum PK parameter of AMG 334 time to maximum observed concentration [Cmax]
- Serum PK parameter of AMG 334 time to maximum concentration [tmax]
- Serum PK parameter of AMG 334 area under the concentration time cure from 0 to 28 days [AUC 0-28days]
- (and 11 more...)
|
60 |
All |
6 Years to 17 Years (Child) |
NCT03499119 |
20160172 |
|
April 18, 2018 |
May 2, 2019 |
March 18, 2020 |
April 17, 2018 |
April 17, 2018 |
|
- Research Site
Little Rock, Arkansas, United States - Research Site
West Palm Beach, Florida, United States - Research Site
Atlanta, Georgia, United States - (and 2 more...)
|
| 36 |
NCT03465904 |
Not yet recruiting |
A Phase III Trial of e-TNS for the Acute Treatment of Migraine |
|
- Device: Verum Cefaly® Abortive Program device
- Device: Sham Cefaly® Abortive Program device
|
Interventional |
Not Applicable |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Pain Freedom at 2 hours
- Most bothersome migraine-associated symptom freedom at 2 hours
- Pain Relief at 2 hours
- (and 4 more...)
|
600 |
All |
18 Years to 65 Years (Adult) |
NCT03465904 |
51401 |
TEAM |
March 2018 |
October 2018 |
October 2018 |
March 14, 2018 |
March 15, 2018 |
|
- Clinical Research Consortium
Tempe, Arizona, United States - Pharmacology Research Institute
Encino, California, United States - Yale University
New Haven, Connecticut, United States - (and 7 more...)
|
| 37 |
NCT02315833 |
Recruiting |
The Efficacy of L-cysteine in Prevention of Headache Attacks in Migraine Patients |
|
- Drug: Acetium
- Drug: Placebo
|
Interventional |
Not Applicable |
- Biohit Oyj
- The Finnish Funding Agency for Technology and Innovation (TEKES)
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Number of migraine attacks (NMA) per evaluation interval
- Number of migraine days (NMD) per evaluation period
|
200 |
All |
18 Years to 65 Years (Adult) |
NCT02315833 |
AC-MIGPREV-1 |
|
June 2014 |
December 2017 |
December 2017 |
December 12, 2014 |
June 23, 2017 |
|
- Terveystalo, Kamppi
Helsinki, Finland - Lääkärikeskus Aava, Helsingin Päänsärkykeskus Oy
Helsinki, Finland - Terveystalo, Jyväskylä
Jyväskylä, Finland - (and 2 more...)
|
| 38 |
NCT03398668 |
Recruiting |
Combined Occipital and Supraorbital Transcutaneous Nerve Stimulation for Treatment of Migraine |
|
- Device: Relievion device- Treatment stimulation
- Device: Relievion Device- Sham stimulation
|
Interventional |
Not Applicable |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Mean change of pain score (measured on a visual analog scale=VAS) at 1 hour compared to baseline
- Mean change of pain score (measured by VAS) at 2 hours compared to baseline (if rescue therapy was not used).
- Mean change of pain score (measured by VAS) at 24 hours compared to baseline (if rescue therapy was not used).
- (and 4 more...)
|
58 |
All |
18 Years to 65 Years (Adult) |
NCT03398668 |
SP301 |
|
February 22, 2018 |
July 30, 2018 |
October 30, 2018 |
January 12, 2018 |
February 23, 2018 |
|
- Laniado Medcial Center
Netanya, Israel
|
| 39 |
NCT03459495 |
Not yet recruiting |
Therapeutic Ultrasound in the Treatment of Migraine |
|
- Device: therapeutic ultrasound
- Device: placebo ultrasound
|
Interventional |
Not Applicable |
- Bursa Yüksek İhtisas Education and Research Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Numeric rating scale (NRS)
- Migraine Disability Assessment Questionnaire Score (MIDAS)
- paracetamol consumption
- the number of migraine attacks per month.
|
58 |
All |
20 Years to 65 Years (Adult) |
NCT03459495 |
2011-KAEK-2018-1/25 |
|
March 10, 2018 |
September 10, 2018 |
September 10, 2018 |
March 9, 2018 |
March 9, 2018 |
|
|
| 40 |
NCT03099070 |
Recruiting |
Acute Stress Response in Migraine Sufferers |
|
- Behavioral: Stress
- Other: Fasting
|
Interventional |
Not Applicable |
- Massachusetts General Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Headache/Medication Use
- Time to next headache attack
- Medication use
- Pain Scores
|
212 |
All |
18 Years to 65 Years (Adult) |
NCT03099070 |
2016P001834 |
|
March 8, 2017 |
May 31, 2020 |
May 31, 2020 |
April 4, 2017 |
April 4, 2017 |
|
- Massachusetts General Hospital
Boston, Massachusetts, United States
|
| 41 |
NCT03488563 |
Recruiting
New |
Study to Determine Safety and Efficacy of B244 in Subjects With Episodic Migraine |
|
- Biological: B244
- Biological: Vehicle
|
Interventional |
Phase 2 |
- AOBiome LLC
- Veristat, Inc.
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
- Mean change in monthly migraine days.
- Mean change in monthly migraine attacks.
- (and 2 more...)
|
303 |
All |
18 Years to 65 Years (Adult) |
NCT03488563 |
MGB244-001 |
|
March 30, 2018 |
November 20, 2018 |
November 20, 2018 |
April 5, 2018 |
April 5, 2018 |
|
- Baptist Health Center for Clinical Research
Little Rock, Arkansas, United States - Collaborative Neuroscience Network, LLC
Long Beach, California, United States - CI Trials
Riverside, California, United States - (and 10 more...)
|
| 42 |
NCT03263897 |
Recruiting |
Feasibility of Using a Mobile Device Controlled Micro-pressure Pulse Insufflator for Acute Migraine Relief |
|
|
Interventional |
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Changes in Symptoms severity scale
- Changes in Symptoms severity scale at 2 hours
- Changes in Symptoms severity scale at 24 hours
|
50 |
All |
20 Years to 65 Years (Adult) |
NCT03263897 |
CI-IRB-20170814001 |
|
August 21, 2017 |
February 28, 2018 |
August 31, 2018 |
August 28, 2017 |
August 28, 2017 |
|
- YRMC: Physiatry, Neurosurgery, Neurology Clinic
Prescott, Arizona, United States - FNOR Clinic Scottsdale
Scottsdale, Arizona, United States
|
| 43 |
NCT03159000 |
Recruiting |
A Research Study of Greater Occipital Nerve Block as a Treatment for Acute Migraine Attacks |
|
- Drug: Saline
- Combination Product: lidocaine/bupivacaine
|
Interventional |
Phase 4 |
- Thomas Jefferson University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Percentage of subjects experiencing headache improvement at 2 hours
- Percentage of subjects experiencing headache improvement 10 minutes
- Percentage of subjects experiencing headache improvement at 30 minutes
- (and 7 more...)
|
50 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT03159000 |
GON/WBY/003 |
|
May 1, 2017 |
December 31, 2017 |
June 30, 2018 |
May 18, 2017 |
May 18, 2017 |
|
- Thomas Jefferson University
Philadelphia, Pennsylvania, United States
|
| 44 |
NCT02784847 |
Not yet recruiting |
A Pilot Trial of Triheptanoin for the Preventive Treatment of Migraine |
|
|
Interventional |
Early Phase 1 |
- University Hospital of Liege
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in monthly migraine days
- Change in mean attack severity
- Change in mean attack duration
- Number of patients who have at least a 50% reduction in monthly migraine days
|
10 |
Female |
18 Years to 65 Years (Adult) |
NCT02784847 |
UX007 |
TRIMI |
June 2016 |
November 2016 |
November 2016 |
May 27, 2016 |
May 27, 2016 |
|
|
| 45 |
NCT02959190 |
Recruiting |
A Study of LY2951742 (Galcanezumab) in Japanese Participants With Migraine |
|
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of Participants who Discontinue
- Pharmacokinetics (PK): Serum Concentration of Galcanezumab
- Plasma Concentration of Calcitonin Gene-Related Peptide (CGRP)
- (and 11 more...)
|
300 |
All |
18 Years to 65 Years (Adult) |
NCT02959190 |
16108
I5Q-JE-CGAP |
|
February 7, 2017 |
October 15, 2018 |
August 24, 2019 |
November 8, 2016 |
April 19, 2018 |
|
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Chofu-shi, Japan - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Fukui, Japan - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Fukuoka, Japan - (and 41 more...)
|
| 46 |
NCT03083860 |
Not yet recruiting |
Evaluation of Migraine Management Mobile App Combined With Electrophysiological Measurements for Identification of Migraine Attack Risk and Beneficial Preventive Actions. |
|
|
Interventional |
Not Applicable |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Device Feasibility
|
- Evaluation of correlation of attention-related electrophysiological changes and patients' migraine dynamics based at-home EEG measurements via mobile phone app.
|
100 |
All |
18 Years to 50 Years (Adult) |
NCT03083860 |
CLD10 |
|
September 2017 |
April 2018 |
December 2018 |
March 20, 2017 |
June 16, 2017 |
|
|
| 47 |
NCT03303105 |
Recruiting |
Long-term Safety and Tolerability of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine |
|
|
Interventional |
Phase 3 |
- Otsuka Pharmaceutical Co., Ltd.
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of Participants with Adverse Events
- Mean change from baseline in the number of migraine days
- Mean change from baseline in the monthly average of migraine days
- (and 2 more...)
|
40 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT03303105 |
406-102-00003
JapicCTI-173726 |
|
January 4, 2018 |
February 2020 |
February 2020 |
October 5, 2017 |
February 16, 2018 |
|
|
| 48 |
NCT03453203 |
Not yet recruiting |
Treatment of Cervical Pain in Chronic Migraine |
|
- Other: Osteopathic Manipulative Treatment Using Counterstrain
|
Interventional |
Not Applicable |
- University Hospitals Cleveland Medical Center
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Care Provider)
- Primary Purpose: Treatment
|
- Treatment of Cervical Pain in Chronic Migraine
|
30 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT03453203 |
UHClevelandMC1 |
|
April 29, 2018 |
December 29, 2018 |
December 29, 2018 |
March 5, 2018 |
March 7, 2018 |
|
|
| 49 |
NCT03303079 |
Recruiting |
Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Chronic Migraine |
|
- Drug: TEV-48125
- Drug: Placebo
|
Interventional |
Phase 2
Phase 3 |
- Otsuka Pharmaceutical Co., Ltd.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Mean change from baseline in the monthly (28-day) average number of headache days of at least moderate severity during the 12-week period after the first dose of Interventional Medicinal Product(IMP)
- Proportion of patients reaching at least 50% reduction in the monthly average number of headache days of at least moderate severity
- Mean change from baseline in the monthly average number of days of use of any acute migraine medications
- (and 2 more...)
|
540 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT03303079 |
406-102-00001
JapicCTI-173723 |
|
December 19, 2017 |
April 2019 |
April 2019 |
October 5, 2017 |
February 16, 2018 |
|
|
| 50 |
NCT03303092 |
Recruiting |
Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Episodic Migraine |
|
- Drug: TEV-48125
- Drug: Placebos
|
Interventional |
Phase 2
Phase 3 |
- Otsuka Pharmaceutical Co., Ltd.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Mean change from baseline in the monthly (28-day) average number of migraine days during the 12-week period after the first dose of Interventional Medicinal Product
- Proportion of patients reaching at least 50% reduction in the monthly average number of migraine days
- Mean change from baseline in the monthly average number of days of use of any acute migraine medications relative to baseline
- Mean change from baseline in the number of migraine days
|
330 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT03303092 |
406-102-00002
JapicCTI-173725 |
|
December 19, 2017 |
December 2018 |
December 2018 |
October 5, 2017 |
February 16, 2018 |
|
|
Create an RSS feed from your search for:
Download the search results for: